TLDR
- Shares of Olema Pharmaceuticals (OLMA) surged 8.5% Monday following a fourth-quarter earnings report that narrowly exceeded analyst projections, with a loss of $0.50 per share versus expectations of $0.51.
- Olema recorded a GAAP net loss totaling $46.1 million during Q4 2025, with full-year losses reaching $162.5 million.
- Stifel maintained its Buy recommendation with a $48 price objective after the earnings release, highlighting sufficient cash reserves extending through mid-2028.
- Recent setbacks in Roche’s persevERA clinical study have sparked concerns regarding the potential outcomes of Olema’s OPERA-02 trial.
- Wall Street consensus shows a “Moderate Buy” stance with a mean price objective of $41, while shares have declined 41% in 2025 despite posting 234% gains over the trailing 12-month period.
Olema Pharmaceuticals (OLMA) experienced an 8.5% rally Monday after delivering fourth-quarter financial results that marginally surpassed Street forecasts. Shares reached an intraday peak of $16.07 before closing near $15.96, advancing from the previous session’s close of $14.71.
Olema Pharmaceuticals, Inc., OLMA
The biopharmaceutical company disclosed a quarterly loss of $0.50 per share for Q4 2025, narrowly outperforming the analyst consensus projection of ($0.51). While the margin was slim, it proved sufficient to drive positive momentum.
Across the complete 2025 fiscal year, Olema recorded a GAAP net loss totaling $162.5 million. Fourth-quarter losses specifically amounted to $46.1 million. Management opted not to host an earnings conference call to discuss the figures.
Notwithstanding ongoing losses, the equity has experienced significant volatility. OLMA has appreciated 234% during the past year, yet simultaneously declined 41% year-to-date prior to Monday’s trading session.
Session volume registered at 518,220 shares — substantially beneath the typical daily average of approximately 1.6 million. The reduced trading activity potentially signals investor hesitation rather than widespread confidence.
Analyst Reaction
Stifel promptly reaffirmed its Buy recommendation alongside a $48 price objective following the earnings announcement. The investment firm emphasized Olema’s financial runway extending through mid-2028 as a significant advantage, providing coverage for numerous developmental milestones preceding the anticipated commercial debut of palazestrant.
Palazestrant is currently under development targeting second- and third-line metastatic breast cancer treatment, with commercialization projected for 2027.
The wider analyst community maintains a generally favorable outlook. Ten research firms maintain Buy recommendations, while one analyst rates the stock as Hold and another as Sell. The consensus price target stands at $41.00 — representing substantial upside from current trading levels.
Oppenheimer upheld its Outperform stance on March 9th. JPMorgan elevated its target from $29 to $32 last November, maintaining an Overweight rating. TD Cowen similarly holds a Buy rating, asserting palazestrant offers superior market positioning compared to rival therapies.
H.C. Wainwright reduced its price objective to $38 while preserving its Buy recommendation following recent clinical trial developments.
The Roche Factor
Earlier this month, Roche disclosed that its persevERA clinical trial — assessing giredestrant combined with palbociclib for first-line metastatic breast cancer — failed to achieve statistical significance on its progression-free survival primary endpoint. Though a favorable numerical trend emerged, the statistical miss carries implications.
The persevERA results are commonly interpreted as indicative for Olema’s Phase 3 OPERA-02 study evaluating palazestrant. Top-line OPERA-02 data isn’t anticipated before 2028 at the earliest.
Stifel noted that comprehensive persevERA findings will likely be unveiled at ASCO 2026, potentially representing the next significant catalyst — or obstacle — for OLMA shares.
Regarding financial positioning, Olema maintains greater cash holdings than debt obligations, with a current ratio of 8.03. The 50-day moving average rests at $24.18, considerably above Monday’s price levels.
Institutional shareholders control 91.78% of outstanding shares. Company insiders, conversely, have been net distributors — divesting approximately 805,501 shares valued at roughly $23 million throughout the preceding three-month period.
The organization’s market capitalization currently approximates $1.09 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
